Can-Fite BioPharma Ltd.
Price Action
Technical Summary
STAGE 2 UPTRENDCan-Fite BioPharma Ltd. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 99), indicating clear outperformance against the broad market. Earnings growth of 36% provides fundamental context to the price action. However, price is extended 39% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.36 | +8.83% | ABOVE |
| 50 SMA | $3.41 | +39.17% | ABOVE |
| 100 SMA | $1.91 | +148.61% | ABOVE |
| 150 SMA | $1.49 | +218.36% | ABOVE |
| 200 SMA | $1.38 | +243.58% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CANF in an uptrend right now?
CANF has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CANF is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CANF overbought or oversold?
CANF's RSI (14) is 69. The stock is in neutral territory, neither overbought nor oversold.
Is CANF outperforming the market?
CANF has a Relative Strength (RS) Rating of 99 out of 99. Yes, CANF is a market leader, outperforming 99% of all stocks over the past 12 months.
Where is CANF in its 52-week range?
CANF is trading at $4.75, which is 96% of its 52-week high ($4.93) and 96% above its 52-week low ($0.17).
How volatile is CANF?
CANF has a Beta of 0.36 and 52-week volatility of 83%. It's less volatile than the S&P 500 - generally more stable.